Detail
Article
Online article
FT
Medvik - BMC
  • Something wrong with this record ?

SalvGlandDx - a comprehensive salivary gland neoplasm specific next generation sequencing panel to facilitate diagnosis and identify therapeutic targets

SN. Freiberger, M. Brada, C. Fritz, S. Höller, A. Vogetseder, M. Horcic, M. Bihl, M. Michal, M. Lanzer, M. Wartenberg, U. Borner, PK. Bode, MA. Broglie, T. Rordorf, GB. Morand, NJ. Rupp

. 2021 ; 23 (5) : 473-487. [pub] 20210418

Language English Country United States

Document type Journal Article

Persistent link   https://www.medvik.cz/link/bmc22012455

Diagnosis of salivary gland neoplasms is often challenging due to their high morphological diversity and overlaps. Several recurrent molecular alterations have been described recently, which can serve as powerful diagnostic tools and potential therapeutic targets (e.g. NTRK or RET fusions). However, current sequential molecular testing can be expensive and time consuming. In order to facilitate the diagnosis of salivary gland neoplasms, we designed an all-in-one RNA-based next generation sequencing panel suitable for the detection of mutations, fusions and gene expression levels (including NR4A3) of 27 genes involved in salivary gland neoplasms. Here we present the validation of the "SalvGlandDx" panel on FFPE histological specimen including fine needle aspiration (FNA) cell block material, against the standard methods currently used at our institution. In a second part we describe selected unique cases in which the SalvGlandDx panel allowed proper diagnosis and new insights into special molecular characteristics of selected salivary gland tumors. We characterize a unique salivary gland adenocarcinoma harboring a ZCCHC7-NTRK2 fusion, a highly uncommon spindle cell and pseudoangiomatoid adenoid-cystic carcinoma with MYBL1-NFIB fusion, and a purely oncocytic mucoepidermoid carcinoma, whereas diagnosis could be made by detection of a CRTC3-MAML2 rearrangement on the cell block specimen of the FNA. Further, a rare case of a SS18-ZBTB7A rearranged low-grade adenocarcinoma previously described as potential spectrum of microsecretory adenocarcinoma, is reported. In addition, features of six cases within the spectrum of polymorphous adenocarcinoma / cribriform adenocarcinoma of salivary gland including PRKD1 p.E710D mutations and novel fusions involving PRKAR2A-PRKD1, SNX9-PRKD1 and ATL2-PRKD3, are described.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc22012455
003      
CZ-PrNML
005      
20220506130446.0
007      
ta
008      
220425s2021 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1016/j.neo.2021.03.008 $2 doi
035    __
$a (PubMed)33878706
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Freiberger, Sandra N $u Department of Pathology and Molecular Pathology, University Hospital Zurich, Zurich, Switzerland; University of Zurich, Zurich, Switzerland
245    10
$a SalvGlandDx - a comprehensive salivary gland neoplasm specific next generation sequencing panel to facilitate diagnosis and identify therapeutic targets / $c SN. Freiberger, M. Brada, C. Fritz, S. Höller, A. Vogetseder, M. Horcic, M. Bihl, M. Michal, M. Lanzer, M. Wartenberg, U. Borner, PK. Bode, MA. Broglie, T. Rordorf, GB. Morand, NJ. Rupp
520    9_
$a Diagnosis of salivary gland neoplasms is often challenging due to their high morphological diversity and overlaps. Several recurrent molecular alterations have been described recently, which can serve as powerful diagnostic tools and potential therapeutic targets (e.g. NTRK or RET fusions). However, current sequential molecular testing can be expensive and time consuming. In order to facilitate the diagnosis of salivary gland neoplasms, we designed an all-in-one RNA-based next generation sequencing panel suitable for the detection of mutations, fusions and gene expression levels (including NR4A3) of 27 genes involved in salivary gland neoplasms. Here we present the validation of the "SalvGlandDx" panel on FFPE histological specimen including fine needle aspiration (FNA) cell block material, against the standard methods currently used at our institution. In a second part we describe selected unique cases in which the SalvGlandDx panel allowed proper diagnosis and new insights into special molecular characteristics of selected salivary gland tumors. We characterize a unique salivary gland adenocarcinoma harboring a ZCCHC7-NTRK2 fusion, a highly uncommon spindle cell and pseudoangiomatoid adenoid-cystic carcinoma with MYBL1-NFIB fusion, and a purely oncocytic mucoepidermoid carcinoma, whereas diagnosis could be made by detection of a CRTC3-MAML2 rearrangement on the cell block specimen of the FNA. Further, a rare case of a SS18-ZBTB7A rearranged low-grade adenocarcinoma previously described as potential spectrum of microsecretory adenocarcinoma, is reported. In addition, features of six cases within the spectrum of polymorphous adenocarcinoma / cribriform adenocarcinoma of salivary gland including PRKD1 p.E710D mutations and novel fusions involving PRKAR2A-PRKD1, SNX9-PRKD1 and ATL2-PRKD3, are described.
650    12
$a nádorové biomarkery $7 D014408
650    _2
$a biopsie $7 D001706
650    _2
$a nádorové buněčné linie $7 D045744
650    12
$a stanovení celkové genové exprese $x metody $7 D020869
650    12
$a vysoce účinné nukleotidové sekvenování $x metody $7 D059014
650    _2
$a lidé $7 D006801
650    _2
$a imunohistochemie $x metody $7 D007150
650    _2
$a hybridizace in situ fluorescenční $7 D017404
650    _2
$a mutace $7 D009154
650    _2
$a stupeň nádoru $7 D060787
650    _2
$a staging nádorů $7 D009367
650    _2
$a fúzní onkogenní proteiny $x genetika $x metabolismus $7 D015514
650    _2
$a nádory slinných žláz $x diagnóza $x farmakoterapie $x genetika $7 D012468
655    _2
$a časopisecké články $7 D016428
700    1_
$a Brada, Muriel $u Department of Pathology and Molecular Pathology, University Hospital Zurich, Zurich, Switzerland; University of Zurich, Zurich, Switzerland
700    1_
$a Fritz, Christine $u Department of Pathology and Molecular Pathology, University Hospital Zurich, Zurich, Switzerland; University of Zurich, Zurich, Switzerland
700    1_
$a Höller, Sylvia $u Department of Pathology and Molecular Pathology, University Hospital Zurich, Zurich, Switzerland; University of Zurich, Zurich, Switzerland
700    1_
$a Vogetseder, Alexander $u Department of Pathology, Cantonal Hospital of Lucerne, Lucerne, Switzerland
700    1_
$a Horcic, Milo $u Institute for Histological and Cytological Diagnostics AG, Aarau, Switzerland
700    1_
$a Bihl, Michel $u Department of Pathology and Medical Genetics, University Hospital Basel, Basel, Switzerland
700    1_
$a Michal, Michal $u Sikl's Department of Pathology, Medical Faculty in Pilsen, Charles University in Prague, Pilsen, Czech Republic; Bioptical Laboratory, Pilsen, Czech Republic
700    1_
$a Lanzer, Martin $u Department of Oral and Maxillofacial Surgery, University Hospital Zurich, Zurich, Switzerland; University of Zurich, Zurich, Switzerland
700    1_
$a Wartenberg, Martin $u Institute of Pathology, University of Bern, Bern, Switzerland
700    1_
$a Borner, Urs $u Department of Otorhinolaryngology, Head and Neck Surgery, Inselspital, Bern University Hospital and University of Bern, Bern, Switzerland
700    1_
$a Bode, Peter K $u Department of Pathology and Molecular Pathology, University Hospital Zurich, Zurich, Switzerland; University of Zurich, Zurich, Switzerland
700    1_
$a Broglie, Martina A $u Department of Otorhinolaryngology, Head and Neck Surgery, University Hospital Zurich, Zurich, Switzerland; University of Zurich, Zurich, Switzerland
700    1_
$a Rordorf, Tamara $u Department of Medical Oncology, University Hospital Zurich, Zurich, Switzerland; University of Zurich, Zurich, Switzerland
700    1_
$a Morand, Grégoire B $u Department of Otorhinolaryngology, Head and Neck Surgery, University Hospital Zurich, Zurich, Switzerland; Department of Otolaryngology-Head and Neck Surgery, Sir Mortimer B. Davis- Jewish General Hospital, McGill University, Montreal, Quebec, Canada; University of Zurich, Zurich, Switzerland
700    1_
$a Rupp, Niels J $u Department of Pathology and Molecular Pathology, University Hospital Zurich, Zurich, Switzerland; University of Zurich, Zurich, Switzerland. Electronic address: niels.rupp@usz.ch
773    0_
$w MED00008883 $t Neoplasia (New York, N.Y.) $x 1476-5586 $g Roč. 23, č. 5 (2021), s. 473-487
856    41
$u https://pubmed.ncbi.nlm.nih.gov/33878706 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y p $z 0
990    __
$a 20220425 $b ABA008
991    __
$a 20220506130438 $b ABA008
999    __
$a ok $b bmc $g 1789872 $s 1163656
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2021 $b 23 $c 5 $d 473-487 $e 20210418 $i 1476-5586 $m Neoplasia $n Neoplasia $x MED00008883
LZP    __
$a Pubmed-20220425

Find record

Citation metrics

Archiving options